Abstract:Abstract Purpose: Neoadjuvant chemotherapy may provide early indication of treatment response. Pathologic complete response (pCR) rate is a surrogate measure of disease-free and overall survival. Anthracycline remain an important component of chemotherapy regimen for breast cancer (BC), while adding taxane confers additional pCR rate. However the combination of anthracycline and trastuzumab remain controversial due to potential increased risk of cardiac event. This trial was designed to compare the efficacy and safety between epirubicin(E) and carboplatin(C) in combination with paclitaxel(P) and trastuzumab(H). Methods: In 13 medical centers, 100 Patients with HER-2/neu immunohistochemistry (IHC) 3+ or FISH-amplified untreated breast cancer, baseline left ventricular ejection fraction (LVEF) of ≥ 55%, ECOG0/1, were enrolled from Sep 2011 to May 2012. Study medication was as follows: Trastuzumab (4 mg/kg loading dose followed by 2 mg/kg) and Pacitaxel (75 mg/m2) weekly combine with Carbopatin (AUC 2) weekly for PCH group or Epirubicin(75 mg/m2) every 3 weeks for PEH group. Patients were recommended to receive 4 or more cycles. The primary endpoint was pCR in the breast and axilla. Secondary endpoints included clinical response, safety. Results: By Aug 16, 2012, 50 patients were randomly assigned to receive PCH regimen and 50 to receive PEH regimen. 49 belonged to TNM stage II, 51 belonged to TNM stage III. The median age was 48 years (range 29 to 65 years). 87 patients completed at least 4 cycles neoadjuvant therapy and then received surgical treatment. pCR in the breast/axilla were found in 38 patients (43.7%; 95% confidence interval [CI]: 33.3%-54.1%). There was no statistic significant difference in PCH and PEH regimen (39.1% vs. 48.8%; p = 0.365). However, PEH regimen achieved significant higher pCR in luminal-B (HER2-poitive) subgroup compared with PCH regimen (55.0% vs. 24.0%; p = 0.033), but not in ERBB2+ subgroup (42.9% vs. 57.1%; p = 0.355). Median LVEF at baseline was 66.0% (range 56.5% to 83.0%), having was no difference between PCH and PEH group (67.0% vs. 65.0%). After 2 cycles in 82 patients, the median LVEF was 64.7% (range 55.0% to 84.0%), there was no difference of LVEF (63.0% vs.66.0%). After 4 cycles in 80 patients, the median LVEF was 66.0% (range 53.0% to 76.0%), no difference was observed between PCH and PEH group (63.0% vs. 66.2%). 8 patients had LVEF decreases of over 10% after 2 cycles, of which 5 patients in PCH group and 3 patients in PEH group. After more than 4 cycles, 3 patients in PCH group and 1 patient in PEH group had LVEF decreases of over 10.0% compared with baseline. No patient experienced LVEF of less than 50% and congestive heart failure (CHF). There was no cardiac death reported. Conclusion: Both PCH and PEH regimens as neoadjuvant chemotherapy have the similar pCR rate for breast cancer patients with HER2-overexpression. PEH might improve the possibility of eradicating invasive cancer in the breast and axilla, especially in the luminal-B (HER2-positive) subtype. PEH is feasible and is not likely to increase the incidence of acute cardiac events compared to PCH. Citation Information: Cancer Res 2013;73(24 Suppl): Abstract nr P4-12-17.

The efficacy and safety of preoperative chemotherapy with triweekly abraxane and cyclophosphamide followed by 5-Fluorouracil, epirubicin, and cyclophosphamide therapy for resectable breast cancer: a multicenter clinical trial

Superior Outcome after Neoadjuvant Chemotherapy with Docetaxel, Anthracycline, and Cyclophosphamide Versus Docetaxel Plus Cyclophosphamide: Results from the NATT Trial in Triple Negative or HER2 Positive Breast Cancer

247P KN026 in Combination with Docetaxel As Neoadjuvant Treatment for HER2+ Early or Locally Advanced Breast Cancer (BC): A Single-Arm, Multicenter, Phase II Study

Neoadjuvant Chemotherapy With Nab-paclitaxel Plus Trastuzumab Followed by 5-Fluorouracil/Epirubicin/Cyclophosphamide for HER2-positive Operable Breast Cancer: A Multicenter Phase II Trial

A randomized study comparing docetaxel/cyclophosphamide (TC), 5-fluorouracil/epirubicin/cyclophosphamide (FEC) followed by TC, and TC followed by FEC for patients with hormone receptor-positive HER2-negative primary breast cancer

A phase II study of weekly carboplatin and nab-paclitaxel with trastuzumab or bevacizumab as neoadjuvant therapy for patients with early-stage nonmetastatic breast cancer.

Efficacy and safety of neoadjuvant chemotherapy with concurrent liposomal-encapsulated doxorubicin, paclitaxel and trastuzumab for human epidermal growth factor receptor 2-positive breast cancer in clinical practice

A Phase II Trial of Weekly Paclitaxel and High-Dose 5-Fluorouracil Plus Leucovorin in Patients with Chemotherapy-Pretreated Metastatic Breast Cancer.

Abstract P4-12-17: Pathological responses and heart safety analysis of trastuzumab and paclitaxel based regimen plus carboplatin or epirubicin as neoadjuvant therapy in clinical stage II-III, HER2-positive breast cancer patients: A phase 2, open-label, multicentre, randomised trial

Efficacy and safety of dose-dense neoadjuvant chemotherapy with nab-paclitaxel followed by epirubicin and cyclophosphamide for operable breast cancer

Phase II trial of weekly nab-paclitaxel and carboplatin treatment with or without trastuzumab as nonanthracycline neoadjuvant chemotherapy for locally advanced breast cancer.

Weekly taxane–anthracycline combination regimen versus tri-weekly anthracycline-based regimen for the treatment of locally advanced breast cancer: a randomized controlled trial

Abstract PO5-18-09: Anthracycline-free neoadjuvant therapy with nab-paclitaxel and carboplatin in non-luminal breast cancer: a single-arm phase II trial

Single-arm, neoadjuvant, phase II trial of pertuzumab and trastuzumab administered concomitantly with weekly paclitaxel followed by 5-fluoruracil, epirubicin, and cyclophosphamide (FEC) for stage I-III HER2-positive breast cancer

Efficacy and safety of trastuzumab, lapatinib, and paclitaxel neoadjuvant treatment with or without prolonged exposure to anti-HER2 therapy, and with or without hormone therapy for HER2-positive primary breast cancer: a randomised, five-arm, multicentre, open-label phase II trial

Efficacy And Safety Analysis Of Trastuzumab And Paclitaxel Based Regimen Plus Carboplatin Or Epirubicin As Neoadjuvant Therapy For Clinical Stage Ii-Iii, Her2-Positive Breast Cancer Patients: A Phase 2, Open-Label, Multicenter, Randomized Trial

Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice

Increased feasibility of weekly epirubicin and paclitaxel as neoadjuvant chemotherapy for locally advanced breast carcinoma

Preoperative Chemotherapy of Continuous Infusion of 5-Fluorouracil, Epirubicin or Pirarubicin and Cyclophosphamine in Operable Primary Breast Cancer

[Neoadjuvant Chemotherapy with Docetaxel Plus Epirubicin for Locally Advanced Breast Cancer: a Multi-Center Phase II Study].

Sequential neoadjuvant chemotherapy using pegylated liposomal doxorubicin and cyclophosphamide followed by taxanes with complete trastuzumab and pertuzumab treatment for HER2-positive breast cancer: A phase II single-arm study